Wang et al. demonstrated that Tan IIA enhanced NSCLC cell sensitivity to gefitinib by downregulating the VEGFR2/Akt pathway (downregulating the phosphorylation levels of VEGFR2 and Akt) in vivo and in vitro.173. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.